CELEXT07 biostimulant enhances grass
fertilization and growth
MONTREAL, July 23, 2019 /CNW/ - Mondias Naturals
Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to
announce the first sale of its CELEXTO7 bio-defense stimulant plant
extract to MontVert.com, a lawn seed and fertilizing company
serving Montreal and the
Monteregie region, in Quebec.
MontVert.com will use CELEXT07 to enhance the properties of its
custom-made fertilizer.
"This first sale is important for Mondias as it continues to
show that CELEXT07 can be used in a multitude of applications,
including the important fertilizer market segment," said
Jean-Philippe Gravel, CEO of
Mondias. "It's also important to note that CELEXT07 is already
authorized for sale under fertilizer regulations in Canada as a specialty fertilizer. Fertilizer
is a growing segment of the overall agricultural industry in
Canada, which produces over 25
million metric tons of fertilizer per year, contributing over
$12 billion annually to Canada's gross domestic product (Source:
Canadian Fertilizer Institute).
"Over the last months, CELEXT07 has generated significant
interest from major players in the horticulture, agriculture, hops
and cannabis sectors," Mr. Gravel added. "Recent test results for
cannabis (see press release dated March 18,
2019) and hops (see press release dated May 16, 2019) were significant milestones
in demonstrating the qualities of CELEXT07 for those markets.
Moreover, ongoing discussions with several potential customers
could lead to further testing and generate additional sales."
"Before buying CELEXT07, we tested the product ourselves and
found that CELEXT07 significantly enhanced the properties of our
custom-made fertilizer when the two were applied together," said
Alec Brazeau, President of
MontVert.com. "The tests showed that we could produce grass that
was denser, greener and faster growing using less fertilizer. In
the next few weeks, we will do other tests to isolate and measure
the direct effect of CELEXT07 on our seeds and lawns."
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the health-care,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries and greenhouses, in collaboration with McGill's Faculty
of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include
the Company's inability to obtain sufficient financing to execute
its business plan; competition; regulation; anticipated and
unanticipated costs and delays; the success of the Company's
research and development strategies; the ability to obtain orphan
drug status; the applicability of the discoveries made; the
successful and timely completion and uncertainties related to the
regulatory approval process; the timing of clinical trials; the
timing and outcomes of regulatory or intellectual property
decisions; and other risks disclosed in the Company's public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify
important factors that could cause actual results or events to
differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements in this news release are made as of the
date of this news release, and the Company does not undertake any
obligation to publicly update them to reflect new information or
subsequent events or otherwise unless required by applicable
securities legislation.
SOURCE Mondias Natural Products Inc.